The American College of Rheumatology (ACR) is apprehensive that “without substantial changes, the demonstration program could disrupt patient access to care, worsen the rheumatology workforce shortage, and exacerbate geographic disparities in access to medical care.”
In recently submitted comments to CMS, the American College of Rheumatology (ACR) expressed concern that the proposed International Pricing Index (IPI), announced November 2018, may disrupt patient access to care.
Specifically, ACR is apprehensive that “without substantial changes, the demonstration program could disrupt patient access to care, worsen the rheumatology workforce shortage, and exacerbate geographic disparities in access to medical care.”
The IPI proposal would allow CMS to implement a reference pricing structure over a 5-year period from 2020-2025, which would enable Medicare to more closely align its payment amount for selected Part B drugs with prices paid in other nations, as well as allow for private-sector negotiations of drugs. CMS believes that the proposal could generate 30% in cost savings, although this figure does not include the prices of biosimilars; instead, it only compares the prices of reference products.
ACR explained in its letter that although it does not have a policy on international reference pricing, the group does support Medicare using its authority to lower drug prices, but does not support mandatory demonstration projects.
“Our current policy is that we support Medicare having the ability to negotiate for reduced drug prices; however, there are many specific pricing mechanisms described in the [IPI] that the ACR cannot support without having specific details on the policy,” read the ACR comment letter.
The organization suggested several modifications to the program:
“We appreciate the opportunity to provide input on the proposed IPI model and are encouraged by the agency’s efforts to make needed therapies more affordable for patients,” said Paula Marchetta, MD, MBA, president of ACR, in a statement. “However, we believe that changes must be made to ensure the proposal does not result in significant disruptions in patient care for the 54 million Americans who live with rheumatic disease.”
The ACR is not the only organization that has expressed concern about the index, as just last month 339 patient, provider, and caregiver groups, on behalf of the Part B Access for Seniors and Physicians Coalition, sent a letter to Congress encouraging lawmakers to block the implementation of the index.
Comments on the IPI model have closed, and CMS will aim to issue a proposed rule this spring.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.